Frederick 2016.
| Methods | Study design: cross‐sectional study (part of longitudinal cohort study REACH) Instrument used to assess fatigue: Pediatric Quality of Life Multidimensional Fatigue Scale Validated questionnaire: yes Cut‐off score or criterion for severe fatigue: NAa Time points at which outcome data were collected: NA, cross‐sectional study Inclusion criteria: survivors of a malignancy other than non‐melanomatous skin cancer, ≥ 2 years from cancer diagnosis, ≥ 1 year from completion of cancer therapy, willing to complete a yearly self‐reported survey of health outcomes, be able to complete forms independently in English Exclusion criteria: nm |
| Participants | Sample characteristics: N of participants original cohort: unknown; N of participants described study group: 268; N of participants study group of interest: 268; N of participants fatigue assessed: 268 Participant characteristics: Tumour type: leukaemia n = 94, HL n = 41, NHL n = 24, bone tumour n = 25, soft tissue sarcoma n = 20, neuroblastoma n = 27, Wilms tumour n = 20, other n = 17 Tumour stage: nm Age at diagnosis: median 6.4 years Time since diagnosis: mean 13.1 years (range 2 ‐ 46) Age at assessment: median 21.4 years (range 12 ‐ 49) F/M: 139/129 BMI: nm Race/ethnicity: White n = 235, African American n = 12, Hispanic n = 8, other n = 13 Marital status: nm Highest completed education level: nm Employment: nm Physical activity level: nm Sleeping problems: nm Psychosocial problems: depressed (Brief symptom inventory‐18): n = 14 Comorbidities/late effects: number of chronic health conditions: 0 n = 107, 1 ‐ 2 n = 123, 3 or more n = 36 asthma n = 55, cardiac condition n = 6, cataract n = 37, diabetes n = 6, elevated cholesterol n = 25, epilepsy (seizures) n = 6, gallstones n = 5, hepatitis n = 6, liver condition n = 7, migraines n = 26, osteoporosis n = 6, thyroid problem n = 46 Genetic factors/mutations: nm |
| Interventions | N of participants surgery: 117 N of participants chemotherapy: 239 N of participants radiotherapy: 171 N of participants BMT: 33 N of participants cranial irradiation: 84 Received chemotherapeutic agent: doxorubicin 194 |
| Outcomes | Severe fatigue: N of participants with severe fatigue: NDa Risk and associated factors: Several demographic and cancer related variables were investigated |
| Notes | Funding sources: nm Declaration of interest: The authors declare that they have no conflict of interest Unclear if this study meets the inclusion criteria 'at least 90% of the participants were under 18 at diagnosis' aAuthors defined fatigued participants as those who scored in the bottom quintile on the PedsQL MDF scale (most fatigued 20%) |